Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Treatment options for mUC following chemo-immunotherapy failure

Aristotelis Bamias, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses non-chemotherapy and non-immunotherapy treatment options for heavily pre-treated patients with locally advanced or metastatic urothelial carcinoma (mUC) at the ESMO education weekend 2020. Dr Bamias highlights two agents that have recently been granted FDA approval: enfortumab vedotin and erdafitinib. Enfortumab vedotin is an antibody-drug conjugate targeting nectin-4 that has been approved based on results from the EV-201 study, which reported a response rate of over 50% (NCT03219333). Erdafitinib has been approved for patients with susceptible FGFR3 or FGFR2 genetic alterations, accounting for around 20% of patients with mUC, based on the results of the BLC2001 study (NCT03390504), which reported a response rate of around 50%. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.